Onyda XR in Bahrain
ADHD in pediatric patients 6 years and older, as monotherapy or adjunct to CNS stimulants · Child & adolescent psychiatry (ADHD)
Onyda XR - overview
Onyda XR (clonidine hydrochloride XR) is manufactured by Tris Pharma and indicated for ADHD stimulant ER, OUT OF SCOPE (amphetamine class, DEA Schedule II; PlatformCo does not handle controlled substances. Fatima's DEA-registered entity may pursue separately.). It is an Extended-release oral liquid α2-adrenergic agonist (non-stimulant, nighttime dosing) approved by the US FDA in 2024 and may be accessible to patients in Bahrain through a Named Patient Program or personal-import pathway.
Access in Bahrain
Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.
How Reserve Meds coordinates access in Bahrain
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Bahrain-specific eligibility.
- Treating physician in Bahrain issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Onyda XR from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Bahrain.
Typical timeline for Bahrain
End-to-end, most requests are completed in 2-6 weeks. Bahrain's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Bahrain ask
- Is the pathway legal in Bahrain? Yes - it operates under Bahrain's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Bahrain able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.